Researchers in the US are investigating the use of a drug currently used in cancer treatment and for preventing organ rejection in kidney transplant recipients. It’s believed ‘rapamycin’ might delay menopause and extend fertility by around five years.
Early results from the study at Columbia University which will eventually include more than 1,000 women, are promising. The team leading the investigation are, Yousin Suh and Zev Williams.
Rapamycin, known for its well-documented effects and side effects, is showing potential in decreasing ovary aging by 20 percent without the common side effects such as high blood pressure and infections. Participants have reported improvements in health, memory, energy levels, and the quality of their skin and hair.
Normally, women lose about 50 eggs every month, with just one egg typically reaching ovulation. However, a small, weekly dose of rapamycin slows this process significantly, reducing the number of eggs released each month to about 15.
The study involves administering 5mg of rapamycin weekly for three months, compared to the 13mg daily dose given to transplant patients. Researchers are cautious about the dosage, as too much could stop ovulation completely. The study will report findings in two years, followed by a larger follow-up study to establish the drug’s efficacy and safety.
The drug is seen as a significant step beyond current menopause treatments, targeting the core of ovarian aging rather than just symptoms. Women in their 30s taking rapamycin could potentially slow the entire aging process, providing more freedom over when to have children.
If successful, rapamycin could offer women in their 30s the option to visit their family doctor to extend their fertility window and possibly continue the treatment post-menopause for additional health benefits.
This research could revolutionize family planning and aging, providing hope to those with age-related fertility issues.
